EE143 Cost-Effectiveness of Ofatumumab Compared with Other Disease-Modifying Therapies for the Treatment of Relapsing Multiple Sclerosis in Greece
Ofatumumab is a high-efficacy disease-modifying therapy (DMT) with a favourable benefit-risk profile recently approved in Greece for the treatment of relapsing multiple sclerosis (RMS). The purpose of this study was to evaluate the cost-effectiveness of ofatumumab vs currently available DMTs (interferon b-1a and -1b, dimethyl fumarate, teriflunomide, glatiramer acetate, ocrelizumab, natalizumab, and fingolimod) for RMS patients from the Greek payer perspective.
Source: Value in Health - Category: International Medicine & Public Health Authors: A Petropoulos, P Cooney, M Patidar, K Gudala, S Tiwari, R Brennan, K Kapsogeorgiou, G Cheilas, J Banhazi Source Type: research
More News: Copaxone | Gilenya | Greece Health | International Medicine & Public Health | Multiple Sclerosis | Study | Tysabri